Startups
GAIA BioMedicine
Fukuoka-based Kyushu University spinout founded in 2015 that develops donor-derived NK-like immune-cell medicines for difficult-to-treat solid tumors. Its GAIA NK-like cell platform uses proprietary culture methods to produce active, tumor-infiltrating cells without genetic modification; mixed-donor manufacturing and frozen formulations are designed to provide a consistent, ready-to-use supply. Lead candidate GAIA-102, also called fulamleucel, is in clinical development for pediatric solid tumors including neuroblastoma and for gastric and pancreatic cancer with peritoneal dissemination. The company combines clinical drug development with cell-manufacturing process development, quality control and production capacity, including a cell-processing facility on the Kyushu University Hospital campus. Its products remain in development.
Founded 2015